The fibroblast activation protein inhibitors market size has grown strongly in recent years. It will grow from $3.02 billion in 2025 to $3.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to fibrotic disease prevalence, unmet medical needs, pharmaceutical r&d growth, hospital specialty care, biologics evolution.
The fibroblast activation protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $4.78 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to precision therapeutics demand, clinical trial expansion, chronic disease burden, targeted drug approvals, specialty pharmacy growth. Major trends in the forecast period include increased focus on anti-fibrotic therapies, expansion of targeted small molecule drugs, growth of chronic inflammatory disease research, rising precision medicine adoption, pipeline expansion in fibrosis indications.
The increasing cancer incidence is expected to propel the growth of the fibroblast activation protein (FAP) inhibitors market in the coming years. Cancer is a disease characterized by the uncontrolled multiplication of abnormal cells, which can invade surrounding tissues and spread to other parts of the body. It arises in various tissues and organs and is classified based on the originating cell or tissue type. The rising incidence of cancer is attributed to aging populations, lifestyle changes, environmental factors, and improved detection methods. Fibroblast activation protein inhibitors are used in cancer treatment to target and disrupt tumor-supporting fibroblasts, enhancing both diagnostic imaging and therapeutic delivery. For instance, in August 2024, according to Macmillan Cancer Support, a UK-based charitable organization supporting cancer patients, over 3 million people in the UK were living with cancer in 2024. This figure is projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing incidence of cancer is driving the growth of the fibroblast activation protein inhibitors market.
Major companies operating in the fibroblast activation protein inhibitors market are focusing on integrating SAR chelator technology with FAP to improve targeted radiopharmaceutical delivery, enhance diagnostic imaging accuracy, and increase therapeutic efficacy. SAR chelator technology uses specialized molecules that tightly bind radioactive metals, allowing precise delivery of radiopharmaceuticals to cancer cells for imaging or therapy. For instance, in December 2024, Clarity Pharmaceuticals, an Australia-based radiopharmaceutical company, launched its novel optimized FAP-targeted radiopharmaceutical. This breakthrough therapy is designed for precision oncology applications, expanding Clarity’s pipeline and offering a highly targeted treatment approach for cancers with high FAP expression, potentially improving both diagnostic accuracy and therapeutic outcomes.
In March 2025, Telix Pharmaceuticals Ltd., an Australia-based radiopharmaceutical company, acquired FAP-targeting theranostic radiopharmaceutical candidates developed by Professor Frank Rösch and collaborators at Johannes Gutenberg University Mainz for an undisclosed amount. By leveraging Telix’s global commercial infrastructure and theranostic expertise, this acquisition aims to accelerate the development of FAP-targeting agents. The acquired assets include preclinical and clinical-stage candidates for imaging and treating a variety of cancers. Johannes Gutenberg University Mainz is a Germany-based university specializing in nuclear chemistry.
Major companies operating in the fibroblast activation protein inhibitors market are Telix Pharmaceuticals Ltd., 3B Pharmaceuticals GmbH, Heidelberg Pharma AG, Clovis Oncology, Fusion Pharmaceuticals, POINT Biopharma (Eli Lilly subsidiary), Pentixapharm AG, iTheranostics, Blue Earth Diagnostics (Bracco Group), SOFIE Biosciences (FAP radioligands), Lantheus Holdings Inc., RadioMedix Inc., ImaginAb Inc., Theragnostics Ltd., Isotopen Technologien München (ITM), Q BioMed Inc., Abcam plc, Sino Biological Inc., Creative Biolabs, Bachem Holding AG.
North America was the largest region in the fibroblast activation protein inhibitors market in 2025. The regions covered in the fibroblast activation protein inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fibroblast activation protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have raised costs in the fibroblast activation protein inhibitors market by affecting imports of small-molecule compounds, biologics, and peptide synthesis materials. Intravenous and injectable therapies are most impacted, particularly in North America and Europe due to dependence on imported biopharmaceutical inputs. Hospital pharmacies face higher drug acquisition costs. Positively, tariffs are encouraging local drug development and fibrosis-focused biomanufacturing.
The fibroblast activation protein inhibitors market research report is one of a series of new reports that provides fibroblast activation protein inhibitors market statistics, including fibroblast activation protein inhibitors industry global market size, regional shares, competitors with a fibroblast activation protein inhibitors market share, detailed fibroblast activation protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the fibroblast activation protein inhibitors industry. This fibroblast activation protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fibroblast activation protein inhibitors are targeted therapies used to treat fibrosis-related disorders by blocking the fibroblast activation protein (FAP) involved in tissue scarring. These small-molecule inhibitors specifically inhibit FAP activity, reducing excessive fibrous tissue formation and improving organ function by slowing fibrosis progression.
The main types of fibroblast activation protein inhibitors include small molecule inhibitors, monoclonal antibodies, and peptide inhibitors. Small molecule inhibitors are low molecular weight compounds designed to penetrate cells and inhibit FAP enzymatic activity. They are being investigated for indications such as interstitial cystitis, Crohn’s disease, irritable bowel syndrome, chronic prostatitis, and others. These inhibitors can be administered orally, intravenously, or subcutaneously, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used across healthcare settings including hospitals, homecare, specialty clinics, and others.
The fibroblast activation protein inhibitors market consists of sales of antibody-drug conjugates, radiolabeled inhibitors, and combination therapies targeting fibroblast activation protein. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The fibroblast activation protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $4.78 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to precision therapeutics demand, clinical trial expansion, chronic disease burden, targeted drug approvals, specialty pharmacy growth. Major trends in the forecast period include increased focus on anti-fibrotic therapies, expansion of targeted small molecule drugs, growth of chronic inflammatory disease research, rising precision medicine adoption, pipeline expansion in fibrosis indications.
The increasing cancer incidence is expected to propel the growth of the fibroblast activation protein (FAP) inhibitors market in the coming years. Cancer is a disease characterized by the uncontrolled multiplication of abnormal cells, which can invade surrounding tissues and spread to other parts of the body. It arises in various tissues and organs and is classified based on the originating cell or tissue type. The rising incidence of cancer is attributed to aging populations, lifestyle changes, environmental factors, and improved detection methods. Fibroblast activation protein inhibitors are used in cancer treatment to target and disrupt tumor-supporting fibroblasts, enhancing both diagnostic imaging and therapeutic delivery. For instance, in August 2024, according to Macmillan Cancer Support, a UK-based charitable organization supporting cancer patients, over 3 million people in the UK were living with cancer in 2024. This figure is projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing incidence of cancer is driving the growth of the fibroblast activation protein inhibitors market.
Major companies operating in the fibroblast activation protein inhibitors market are focusing on integrating SAR chelator technology with FAP to improve targeted radiopharmaceutical delivery, enhance diagnostic imaging accuracy, and increase therapeutic efficacy. SAR chelator technology uses specialized molecules that tightly bind radioactive metals, allowing precise delivery of radiopharmaceuticals to cancer cells for imaging or therapy. For instance, in December 2024, Clarity Pharmaceuticals, an Australia-based radiopharmaceutical company, launched its novel optimized FAP-targeted radiopharmaceutical. This breakthrough therapy is designed for precision oncology applications, expanding Clarity’s pipeline and offering a highly targeted treatment approach for cancers with high FAP expression, potentially improving both diagnostic accuracy and therapeutic outcomes.
In March 2025, Telix Pharmaceuticals Ltd., an Australia-based radiopharmaceutical company, acquired FAP-targeting theranostic radiopharmaceutical candidates developed by Professor Frank Rösch and collaborators at Johannes Gutenberg University Mainz for an undisclosed amount. By leveraging Telix’s global commercial infrastructure and theranostic expertise, this acquisition aims to accelerate the development of FAP-targeting agents. The acquired assets include preclinical and clinical-stage candidates for imaging and treating a variety of cancers. Johannes Gutenberg University Mainz is a Germany-based university specializing in nuclear chemistry.
Major companies operating in the fibroblast activation protein inhibitors market are Telix Pharmaceuticals Ltd., 3B Pharmaceuticals GmbH, Heidelberg Pharma AG, Clovis Oncology, Fusion Pharmaceuticals, POINT Biopharma (Eli Lilly subsidiary), Pentixapharm AG, iTheranostics, Blue Earth Diagnostics (Bracco Group), SOFIE Biosciences (FAP radioligands), Lantheus Holdings Inc., RadioMedix Inc., ImaginAb Inc., Theragnostics Ltd., Isotopen Technologien München (ITM), Q BioMed Inc., Abcam plc, Sino Biological Inc., Creative Biolabs, Bachem Holding AG.
North America was the largest region in the fibroblast activation protein inhibitors market in 2025. The regions covered in the fibroblast activation protein inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fibroblast activation protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have raised costs in the fibroblast activation protein inhibitors market by affecting imports of small-molecule compounds, biologics, and peptide synthesis materials. Intravenous and injectable therapies are most impacted, particularly in North America and Europe due to dependence on imported biopharmaceutical inputs. Hospital pharmacies face higher drug acquisition costs. Positively, tariffs are encouraging local drug development and fibrosis-focused biomanufacturing.
The fibroblast activation protein inhibitors market research report is one of a series of new reports that provides fibroblast activation protein inhibitors market statistics, including fibroblast activation protein inhibitors industry global market size, regional shares, competitors with a fibroblast activation protein inhibitors market share, detailed fibroblast activation protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the fibroblast activation protein inhibitors industry. This fibroblast activation protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fibroblast activation protein inhibitors are targeted therapies used to treat fibrosis-related disorders by blocking the fibroblast activation protein (FAP) involved in tissue scarring. These small-molecule inhibitors specifically inhibit FAP activity, reducing excessive fibrous tissue formation and improving organ function by slowing fibrosis progression.
The main types of fibroblast activation protein inhibitors include small molecule inhibitors, monoclonal antibodies, and peptide inhibitors. Small molecule inhibitors are low molecular weight compounds designed to penetrate cells and inhibit FAP enzymatic activity. They are being investigated for indications such as interstitial cystitis, Crohn’s disease, irritable bowel syndrome, chronic prostatitis, and others. These inhibitors can be administered orally, intravenously, or subcutaneously, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used across healthcare settings including hospitals, homecare, specialty clinics, and others.
The fibroblast activation protein inhibitors market consists of sales of antibody-drug conjugates, radiolabeled inhibitors, and combination therapies targeting fibroblast activation protein. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Fibroblast Activation Protein Inhibitors Market Characteristics
3. Fibroblast Activation Protein Inhibitors Market Supply Chain Analysis
4. Global Fibroblast Activation Protein Inhibitors Market Trends and Strategies
5. Fibroblast Activation Protein Inhibitors Market Analysis of End Use Industries
7. Global Fibroblast Activation Protein Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Fibroblast Activation Protein Inhibitors Total Addressable Market (TAM) Analysis for the Market
9. Fibroblast Activation Protein Inhibitors Market Segmentation
10. Fibroblast Activation Protein Inhibitors Market Regional and Country Analysis
11. Asia-Pacific Fibroblast Activation Protein Inhibitors Market
12. China Fibroblast Activation Protein Inhibitors Market
13. India Fibroblast Activation Protein Inhibitors Market
14. Japan Fibroblast Activation Protein Inhibitors Market
15. Australia Fibroblast Activation Protein Inhibitors Market
16. Indonesia Fibroblast Activation Protein Inhibitors Market
17. South Korea Fibroblast Activation Protein Inhibitors Market
18. Taiwan Fibroblast Activation Protein Inhibitors Market
19. South East Asia Fibroblast Activation Protein Inhibitors Market
20. Western Europe Fibroblast Activation Protein Inhibitors Market
21. UK Fibroblast Activation Protein Inhibitors Market
22. Germany Fibroblast Activation Protein Inhibitors Market
23. France Fibroblast Activation Protein Inhibitors Market
24. Italy Fibroblast Activation Protein Inhibitors Market
25. Spain Fibroblast Activation Protein Inhibitors Market
26. Eastern Europe Fibroblast Activation Protein Inhibitors Market
27. Russia Fibroblast Activation Protein Inhibitors Market
28. North America Fibroblast Activation Protein Inhibitors Market
29. USA Fibroblast Activation Protein Inhibitors Market
30. Canada Fibroblast Activation Protein Inhibitors Market
31. South America Fibroblast Activation Protein Inhibitors Market
32. Brazil Fibroblast Activation Protein Inhibitors Market
33. Middle East Fibroblast Activation Protein Inhibitors Market
34. Africa Fibroblast Activation Protein Inhibitors Market
36. Fibroblast Activation Protein Inhibitors Market Competitive Landscape and Company Profiles
37. Fibroblast Activation Protein Inhibitors Market Other Major and Innovative Companies
40. Fibroblast Activation Protein Inhibitors Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Fibroblast Activation Protein Inhibitors Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses fibroblast activation protein inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for fibroblast activation protein inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fibroblast activation protein inhibitors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Small Molecule Inhibitors; Monoclonal Antibodies; Peptide Inhibitors2) By Indication: Crohn’s; Irritable Bowel; Chronic Prostatitis; Other Indications
3) By Route Of Administration: Oral; Intravenous; Subcutaneous
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Small Molecule Inhibitors: Protease Inhibitors; Multi-Targeted Agents2) By Monoclonal Antibodies: Humanized Antibodies; Fully Human Antibodies; Bispecific Antibodies
3) By Peptide Inhibitors: Synthetic Peptides; Natural Peptide Derivatives; Peptide-Based Conjugates
Companies Mentioned: Telix Pharmaceuticals Ltd.; 3B Pharmaceuticals GmbH; Heidelberg Pharma AG; Clovis Oncology; Fusion Pharmaceuticals; POINT Biopharma (Eli Lilly subsidiary); Pentixapharm AG; iTheranostics; Blue Earth Diagnostics (Bracco Group); SOFIE Biosciences (FAP radioligands); Lantheus Holdings Inc.; RadioMedix Inc.; ImaginAb Inc.; Theragnostics Ltd.; Isotopen Technologien München (ITM); Q BioMed Inc.; Abcam plc; Sino Biological Inc.; Creative Biolabs; Bachem Holding AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Fibroblast Activation Protein Inhibitors market report include:- Telix Pharmaceuticals Ltd.
- 3B Pharmaceuticals GmbH
- Heidelberg Pharma AG
- Clovis Oncology
- Fusion Pharmaceuticals
- POINT Biopharma (Eli Lilly subsidiary)
- Pentixapharm AG
- iTheranostics
- Blue Earth Diagnostics (Bracco Group)
- SOFIE Biosciences (FAP radioligands)
- Lantheus Holdings Inc.
- RadioMedix Inc.
- ImaginAb Inc.
- Theragnostics Ltd.
- Isotopen Technologien München (ITM)
- Q BioMed Inc.
- Abcam plc
- Sino Biological Inc.
- Creative Biolabs
- Bachem Holding AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.32 Billion |
| Forecasted Market Value ( USD | $ 4.78 Billion |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
